Abstract
Background
Neonates with congenital diaphragmatic hernia (CDH) suffer from pulmonary hypoplasia (PH) and may require extracorporeal membrane oxygenation (ECMO) and anticoagulation, often with unfractionated heparin (UFH). UFH interacts with vascular endothelial growth factor (VEGF), a factor important in lung development. We investigated the effects of UFH, low molecular weight heparin (LMWH), and bivalirudin (BV) on a murine model of compensatory lung growth (CLG).
Methods
Proliferation and apoptosis were assessed in microvascular lung endothelial cells (HMVEC-L) treated with anticoagulants. Eight-week-old C57Bl/6J mice underwent left pneumonectomy and anticoagulation with low- or high-dose UFH, LMWH, BV, or saline control. Lung volume, pulmonary function tests, morphometrics, treadmill exercise tolerance, and pulmonary protein expression were examined.
Results
UFH and LMWH inhibited HMVEC-L proliferation. BV promoted proliferation and decreased apoptosis. UFH and LMWH-treated mice had reduced lung volume, total lung capacity, alveolar volume, and septal surface area compared to controls, while BV did not affect these measures. UFH and LMWH-treated mice had lower exercise tolerance compared to controls.
Conclusions
UFH and LMWH impair pulmonary growth, alveolarization, and exercise tolerance, while BV does not. Alternative anticoagulants to heparin may be considered to improve functional outcomes for neonates with CDH and pulmonary hypoplasia.
Impact
-
Unfractionated heparin and low molecular weight heparin may modify compensatory lung growth by reducing microvascular lung endothelial cell proliferation and affecting pulmonary angiogenic signaling.
-
Functional effects of unfractionated heparin and low molecular weight heparin on murine compensatory lung growth include reduction in exercise tolerance.
-
Bivalirudin, a direct thrombin inhibitor, may increase microvascular lung endothelial cell proliferation and preserves lung volume, alveolarization, and exercise tolerance in a murine compensatory lung growth model.
-
Anticoagulants alternative to heparin should be further investigated for use in neonates with pulmonary hypoplastic diseases to optimize lung growth and development and improve outcomes.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 14 print issues and online access
$259.00 per year
only $18.50 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
All data generated or analyzed during this study are included in this published article (and its Supplementary Information files). For further details regarding the methods or materials, please contact the corresponding author.
References
Tsao, K. et al. Congenital diaphragmatic hernia in the preterm infant. Surgery 148, 404–410 (2010).
Seetharamaiah, R. et al. Factors associated with survival in infants with congenital diaphragmatic hernia requiring extracorporeal membrane oxygenation: a report from the Congenital Diaphragmatic Hernia Study Group. J. Pediatr. Surg. 44, 1315–1321 (2009).
Burgos, C. M. & Frenckner, B. Addressing the hidden mortality in CDH: A population-based study. J. Pediatr. Surg. 52, 522–525 (2017).
Hsia, C. C. Signals and mechanisms of compensatory lung growth. J. Appl. Physiol. 97, 1992–1998 (2004).
Voswinckel, R. et al. Characterisation of post-pneumonectomy lung growth in adult mice. Eur. Respir. J. 24, 524–532 (2004).
Sakurai, M. K. et al. Vascular endothelial growth factor accelerates compensatory lung growth after unilateral pneumonectomy. Am. J. Physiol. Lung Cell. Mol. Physiol. 292, L742–L747 (2007).
Dao, D. T. et al. Vascular endothelial growth factor accelerates compensatory lung growth by increasing the alveolar units. Pediatr. Res. 83, 1182–1189 (2018).
Yu, L. J. et al. Investigation of the mechanisms of VEGF-mediated compensatory lung growth: the role of the VEGF heparin-binding domain. Sci. Rep. 11, 11827 (2021).
Dao, D. T. et al. Heparin impairs angiogenic signaling and compensatory lung growth after left pneumonectomy. Angiogenesis 21, 837–848 (2018).
East, M. A., Landis, D. I., Thompson, M. A. & Annex, B. H. Effect of single dose of intravenous heparin on plasma levels of angiogenic growth factors. Am. J. Cardiol. 91, 1234–1236 (2003).
Kapur, N. K. et al. Distinct effects of unfractionated heparin versus bivalirudin on circulating angiogenic peptides. PLoS ONE 7, e34344 (2012).
Sakurai, M. K. et al. Pneumonectomy in the mouse: technique and perioperative management. J. Invest. Surg. 18, 201–205 (2005).
Scherle, W. A simple method for volumetry of organs in quantitative stereology. Mikroskopie 26, 57–60 (1970).
Ochs, M. & Muhlfeld, C. Quantitative microscopy of the lung: a problem-based approach. Part 1: Basic principles of lung stereology. Am. J. Physiol. Lung Cell. Mol. Physiol. 305, L15–L22 (2013).
Muhlfeld, C. & Ochs, M. Quantitative microscopy of the lung: a problem-based approach. Part 2: stereological parameters and study designs in various diseases of the respiratory tract. Am. J. Physiol. Lung Cell. Mol. Physiol. 305, L205–L221 (2013).
Dougherty, J. P., Springer, D. A. & Gershengorn, M. C. The treadmill fatigue test: a simple, high-throughput assay of fatigue-like behavior for the mouse. J. Vis. Exp. 54052 (2016).
Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402–408 (2001).
Tsikis, S. T. et al. Lipopolysaccharide-induced murine lung injury results in long-term pulmonary changes and downregulation of angiogenic pathways. Sci. Rep. 12, 10245 (2022).
Khorana, A. A., Sahni, A., Altland, O. D. & Francis, C. W. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler. Thromb. Vasc. Biol. 23, 2110–2115 (2003).
Collen, A. et al. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res. 60, 6196–6200 (2000).
Furue, M. K. et al. Heparin promotes the growth of human embryonic stem cells in a defined serum-free medium. Proc. Natl Acad. Sci. USA 105, 13409–13414 (2008).
Teran, M. & Nugent, M. A. Synergistic binding of vascular endothelial growth factor-A and its receptors to heparin selectively modulates complex affinity. J. Biol. Chem. 290, 16451–16462 (2015).
Sack, K. D., Teran, M. & Nugent, M. A. Extracellular matrix stiffness controls VEGF signaling and processing in endothelial cells. J. Cell. Physiol. 231, 2026–2039 (2016).
Dao, D. T. et al. Heparin-binding epidermal growth factor-like growth factor as a critical mediator of tissue repair and regeneration. Am. J. Pathol. 188, 2446–2456 (2018).
Shibuya, M. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J. Biochem. 153, 13–19 (2013).
Dao, D. T. et al. A paradoxical method to enhance compensatory lung growth: Utilizing a VEGF inhibitor. PLoS ONE 13, e0208579 (2018).
Tazawa, S. et al. Heparin stimulates the proliferation of bovine aortic endothelial cells probably through activation of endogenous basic fibroblast growth factor. Thromb. Res. 72, 431–439 (1993).
Hales, C. A., Kradin, R. L., Brandstetter, R. D. & Zhu, Y. J. Impairment of hypoxic pulmonary artery remodeling by heparin in mice. Am. Rev. Respir. Dis. 128, 747–751 (1983).
Hassoun, P. M., Thompson, B. T. & Hales, C. A. Partial reversal of hypoxic pulmonary hypertension by heparin. Am. Rev. Respir. Dis. 145, 193–196 (1992).
Halayko, A. J., Rector, E. & Stephens, N. L. Airway smooth muscle cell proliferation: characterization of subpopulations by sensitivity to heparin inhibition. Am. J. Physiol. 274, L17–L25 (1998).
Zhao, G. et al. Heparin reduces overcirculation-induced pulmonary artery remodeling through p38 MAPK in piglet. Ann. Thorac. Surg. 99, 1677–1684 (2015).
Al-Ansari, E. et al. Low-molecular-weight heparin inhibits hypoxic pulmonary hypertension and vascular remodeling in guinea pigs. Chest 132, 1898–1905 (2007).
Kays, D. W. et al. Outcomes in the physiologically most severe congenital diaphragmatic hernia (CDH) patients: whom should we treat? J. Pediatr. Surg. 50, 893–897 (2015).
Snyder, C. W. et al. A perioperative bivalirudin anticoagulation protocol for neonates with congenital diaphragmatic hernia on extracorporeal membrane oxygenation. Thromb. Res. 193, 198–203 (2020).
Hamzah, M., Jarden, A. M., Ezetendu, C. & Stewart, R. Evaluation of bivalirudin as an alternative to heparin for systemic anticoagulation in pediatric extracorporeal membrane oxygenation. Pediatr. Crit. Care Med. 21, 827–834 (2020).
Stoll, B. J. et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. JAMA 314, 1039–1051 (2015).
Higgins, R. D. et al. Bronchopulmonary dysplasia: Executive Summary of a Workshop. J. Pediatr. 197, 300–308 (2018).
Acknowledgements
The authors acknowledge the neurodevelopmental behavior core at Boston Children’s Hospital CHB IDDRC, 1U54HD090255.
Funding
Research funding for this study was provided by the Richard and Sandra Cummings Research Fellowship of the Beth Israel Deaconess Medical Center Department of Surgery (L.J.Y.), Boston Children’s Hospital Surgical Foundation (L.J.Y., V.H.K., J.D.S., M.P.), The Boston Children’s Hospital Vascular Biology Program (all), the Joshua Ryan Rappaport Fellowship of the Boston Children’s Hospital Department of Surgery (L.J.Y.), the National Institutes of Health grants 2T32DK007754–21 (S.T.T.) and 5T32HL007734 (D.T.D., S.C.F.), and the Howard Hughes Medical Institute (B.S.C.).
Author information
Authors and Affiliations
Contributions
Conceptualization: V.H.K., L.J.Y., D.T.D., M.P. Data curation: L.J.Y., V.H.K., S.T.T., J.D.S., A.P., B.S.C., S.C.F. Formal analysis: L.J.Y., V.H.K., P.D.M. Funding acquisition: L.J.Y., M.P. Investigation: V.H.K., L.J.Y., S.T.T., D.T.D., A.P. Methodology: V.H.K., L.J.Y., S.T.T., D.T.D., S.C.F. Project administration: A.P. Supervision: M.P. Writing—original draft: L.J.Y., V.H.K., S.T.T. Writing—review and editing: L.J.Y., S.T.T., V.H.K., D.T.D., J.D.S., P.D.M., S.C.F., B.S.C., H.K., M.P.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Yu, L.J., Ko, V.H., Tsikis, S.T. et al. Effects of systemic anticoagulation in a murine model of compensatory lung growth. Pediatr Res 93, 1846–1855 (2023). https://doi.org/10.1038/s41390-022-02323-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41390-022-02323-1